by Thomas Rønn | Jul 10, 2023 | Press Releases
Eir Ventures celebrates 3 years anniversary. On July 10, 2020, Eir Ventures I was launched with the announcement of the first close of our fund. Since the launch, Eir Ventures have completed investments in 17 pioneering life science companies; 5 companies have taken...
by Thomas Rønn | Jul 9, 2023 | Press Releases
Eir Ventures welcomes Lovisa Backemar as Principal in the Eir Ventures Team. Lovisa is a Medical Doctor and holds a PhD in clinical epidemiology from the Karolinska Institute. Prior to joining Eir Ventures, Lovisa served as Head of Business Development at the Swedish...
by Thomas Rønn | May 9, 2023 | Press Releases
Eir Ventures are delighted to announce our most recent investment in RAPP. The company was founded in Sweden based on Professor Ulrica Nilsson’s research, offering an evidence-based, interactive, and patient-centric digital platform that addresses several needs in the...
by Thomas Rønn | Apr 11, 2023 | Press Releases
Eir Ventures are delighted to announce our most recent investment in GutCRINE. The company is a pioneering spin out from Copenhagen University developing a new first in class therapy targeting metabolic and age-related diseases like obesity, type 2 diabetes,...
by Thomas Rønn | Oct 25, 2022 | Press Releases
Henlez mission is to transform the management of skin conditions by using enzymes. Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic...
by Thomas Rønn | Sep 14, 2022 | Press Releases
Pretzel is developing treatments to address the genetic roots of mitochondrial dysfunction. Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug...
by Thomas Rønn | Jul 6, 2022 | Press Releases
Hoba Therapeutics is Danish biotech developing restorative treatments for pain, hearing loss, and sensory neuron disorders. HB-086 is under development for the treatment of pain in multiple chronic neuropathic pain indications. HB-086 is a non-opioid compound with a...
by Thomas Rønn | Jul 1, 2022 | Press Releases
Attgeno develops novel nitric oxide donators which are selective for the pulmonary circulation, making them safe and without systemic side-effects.Attgeno has developed Supernitro, a first in class therapy for the specific delivery of Nitric Oxide (NO) in the lung...
by Thomas Rønn | Jun 3, 2022 | Press Releases
Eir ventures has established itself as a well-respected professional investor in the Nordic life science ecosystem and will continue to build the organization and network to key stakeholders in the region. In accordance with this aim, Eir Ventures is expanding the...
Recent Comments